The National Heart, Lung, and Blood Institute (NHLBI) awarded a $739,236 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Childrens Hospital Medical Center in Cincinnati, Ohio. The funding will support a research project titled "Cellular Determinants of Responsiveness to mTOR Inhibitors in LAM" from February 1, 2025 through November 30, 2028.
The project aims to elucidate the mechanisms underlying insensitivity to sirolimus, an mTOR inhibitor drug approved to treat lymphangioleiomyomatosis (LAM), a rare and debilitating lung disease. The research will identify molecular determinants of acquired sirolimus insensitivity, the role of YAP-WNT crosstalk in promoting a "LAM cell stemness state" that drives sirolimus insensitivity, and evaluate the potential for YAP-WNT inhibition to restore sirolimus sensitivity in preclinical LAM models. The findings are expected to inform new therapeutic strategies to induce remission in LAM patients.
Generated 3/4/25, 2:23 AM